MedTrace Logo

MUC1 Vaccine for Triple-negative Breast Cancer

NCT00986609 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2018-07-23

No results posted yet for this study

Summary

RATIONALE:

Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Giving booster vaccinations may make a stronger immune response and prevent or delay the recurrence of cancer.

PURPOSE:

To evaluate the efficacy of poly-ICLC + MUCI peptide vaccine in boosting the immunologic response to MUCI in patients with triple-negative BC

Conditions

  • Breast Cancer
  • Inflammatory Breast Cancer
  • Stage I Breast Cancer
  • Stage II Breast Cancer
  • Stage IIIA Breast Cancer
  • Stage IIIB Breast Cancer
  • Stage IIIC Breast Cancer
  • Triple-negative Breast Cancer

Interventions

BIOLOGICAL

MUC-1 peptide vaccine

Given subcutaneously

BIOLOGICAL

poly ICLC

Given intramuscularly

BIOLOGICAL

MUC1 peptide-poly-ICLC adjuvant vaccine

Receive adjuvant vaccination

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

enzyme-linked immunosorbent assay

Correlative studies

OTHER

flow cytometry

Correlative studies

Sponsors & Collaborators

  • Joseph Baar, MD, PhD

    lead OTHER

Principal Investigators

  • Joseph Baar, MD · Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-19
Primary Completion
2013-08-29
Completion
2016-01-21

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00986609 on ClinicalTrials.gov